There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Glaukos (GKOS – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
Glaukos (GKOS)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Glaukos, with a price target of $145.00. The company’s shares closed last Monday at $131.38, close to its 52-week high of $139.51.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Glaukos with a $141.86 average price target, which is an 8.8% upside from current levels. In a report issued on October 28, Jefferies also maintained a Buy rating on the stock with a $155.00 price target.
See today’s best-performing stocks on TipRanks >>
Vertex Pharmaceuticals (VRTX)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $555.00. The company’s shares closed last Monday at $472.80.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $515.11 average price target, which is an 8.7% upside from current levels. In a report issued on October 20, BMO Capital also maintained a Buy rating on the stock with a $566.00 price target.
Read More on GKOS:
